A Study of Radium-223 in Combination With Tasquinimod in Bone-only Metastatic Castration-Resistant Prostate Cancer
Status:
Withdrawn
Trial end date:
2017-07-01
Target enrollment:
Participant gender:
Summary
This is a Phase I/Ib study of Radium-223 in combination with Tasquinimod for patients with
bone metastases from castration-resistant prostate cancer (CRPC).
The investigators propose to determine the spectrum of tolerability of the combination of
tasquinimod and radium-223 and determine a dose for a subsequent randomized phase II study
(first cohort) and the proportion of men with bone-specific alkaline phosphatase response
(second cohort).
Phase:
Phase 1
Details
Lead Sponsor:
Sidney Kimmel Comprehensive Cancer Center Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins